Daily Funding Alert by BSA | 17 July 2026 | Mandrake Bio Raises Rs 16 Cr Pre-Seed Led by Activate and Antler
Mandrake Bio, a Bengaluru-based AI and biotechnology startup, has raised Rs 16 crore in a pre-seed funding round co-led by Activate and Antler. Moneycontrol reported the round on 16 July 2026 and Economic…
Funding snapshot
Mandrake Bio, a Bengaluru-based AI and biotechnology startup, has raised Rs 16 crore in a pre-seed funding round co-led by Activate and Antler. Moneycontrol reported the round on 16 July 2026 and Economic Times also covered the raise. The round included participation from Spectrum Impact, DeVC and angel investors including Vijay Chandru, Paras Chopra, Sanjiv Rangrass and Vatsal Dusad.
Mandrake Bio website: https://www.mandrakebio.com/
Activate: no single official website was reliably available from the public search result used today; public coverage identifies it as an AI-focused early-stage fund associated with Aakrit Vaish and Pratyush Choudhury.
Antler India website: https://www.antler.co/location/india
Spectrum Impact website: https://spectrum-impact.org/
DeVC website: https://www.devc.com/
Deal details
| Item | Detail |
|---|---|
| Startup | Mandrake Bio |
| Website | https://www.mandrakebio.com/ |
| Round | Pre-seed |
| Amount | Rs 16 crore |
| Lead/co-lead investors | Activate and Antler |
| Other participants | Spectrum Impact, DeVC and angel investors |
| Sector | AI, biotechnology, protein design, gene editing |
| Location signal | Bengaluru |
| Reported use of funds | AI protein-design platform, research hiring and wet-lab validation |
What Mandrake Bio does
Mandrake Bio says it is building AI-native protein design and gene-editing infrastructure. Its website describes a full-stack protein-design company creating molecular machinery for next-generation gene editing, with work across function-aware generation, biological data and wet-lab validation.
In simple founder language, the company is trying to use generative AI, structural biology and experiments to design programmable gene-editing enzymes, instead of only modifying tools discovered in nature. The applications mentioned publicly include agriculture and medicine.
Why investors may have funded it
1. AI plus science is becoming a serious venture category
Investors are increasingly looking for technical teams that can apply AI beyond chat and workflow software. Protein design and gene editing sit in a high-risk, high-upside category where intellectual property, research depth and validation can create defensibility.
2. The market is large but technically hard
Agriculture and medicine both have large unsolved problems. If a startup can reduce development timelines or improve precision in gene-editing workflows, the commercial potential can be significant.
3. Early deeptech investors back capability before revenue
At pre-seed, investors often evaluate founder quality, scientific thesis, experiments, data advantage, lab access, partner ecosystem and IP direction. Revenue may be limited, but the technology path must be credible.
4. Investor mix fits the round
Antler publicly positions itself as an early-stage AI investor in India. DeVC describes itself as early-stage capital with founder/operator support. Spectrum Impact focuses on large societal problems with financial, societal and environmental return objectives. That mix fits a biotech platform with agriculture and medical possibilities.
What to expect over the next 3 years
| Timeline | Possible milestone to watch |
|---|---|
| 0-12 months | Research hiring, platform build-out, assays and early validation |
| 12-24 months | Stronger proof points, partnerships, patent/IP activity and scientific publication signals |
| 24-36 months | Application-specific pilots, agriculture or therapeutic partnerships, larger seed/Series A readiness |
This is an inference from the reported use of funds and the nature of deeptech company-building, not a company-announced forecast.
How similar founders can approach relevant investors
Founders building AI-native deeptech, biotech, climate, hardware or scientific infrastructure should not send a generic SaaS pitch. They should prepare a clear technical memo, evidence of experiments, IP ownership, regulatory map, founder-science credibility and a practical 18-month use-of-funds plan.
Investor outreach checklist
- Identify investors that understand early technical risk.
- Show why the problem is large and urgent.
- Explain why your team can solve it better than labs, incumbents or global competitors.
- Present early validation honestly.
- Keep claims precise and source-backed.
- Prepare a legal and IP data room before the first partner meeting.
Legal, tax and compliance documents to prepare
| Area | Documents |
|---|---|
| Corporate | COI, MOA, AOA, board minutes, registers, cap table |
| Funding | Term sheet, SHA/SSA drafts, valuation report, use-of-funds note |
| FEMA | FIRC, KYC, FC-GPR plan, sectoral review if foreign investors participate |
| Tax | PAN, TAN, ITR, GST/TDS status, tax-demand check |
| IP | Founder assignment, employee invention assignment, patent notes, lab notebooks |
| ESOP | ESOP scheme, grants, vesting tracker, board/shareholder approvals |
| Contracts | Consultant, lab, research, vendor, employment and confidentiality agreements |
| Data room | Scientific evidence, risk notes, regulatory map, insurance and compliance tracker |
Founder takeaway
Mandrake Bio’s round is a useful signal for deeptech founders: money can move early when the thesis is sharp, the team is credible, and the compliance/IP base is clean. The Best CS Firm In India mindset is to prepare the cap table, FEMA route, IP ownership and data room before the investor asks for them.
Sources
- Moneycontrol funding report: https://www.moneycontrol.com/news/business/funding/mandrake-bio-raises-rs-16-crore-pre-seed-funding-co-led-by-activate-antler-13975423.html
- Economic Times report: https://m.economictimes.com/tech/artificial-intelligence/mandrake-bio-raises-rs-16-crore-to-build-ai-powered-gene-editing-platform-for-agriculture-medicine/articleshow/132431719.cms
- Mandrake Bio: https://www.mandrakebio.com/
- Antler India: https://www.antler.co/location/india
- Spectrum Impact: https://spectrum-impact.org/
- DeVC: https://www.devc.com/
FAQ Section
How much funding did Mandrake Bio raise?
Mandrake Bio raised Rs 16 crore in a pre-seed round, as reported by Moneycontrol and Economic Times.
Who led Mandrake Bio’s funding round?
The round was co-led by Activate and Antler, with participation from Spectrum Impact, DeVC and angel investors.
What sector does Mandrake Bio operate in?
Mandrake Bio operates at the intersection of AI, biotechnology, protein design and gene editing.
What should deeptech founders prepare before investor outreach?
They should prepare technical proof, IP ownership documents, cap table, FEMA readiness, lab/research contracts, compliance notes and a clear use-of-funds plan.
Why is IP documentation important for biotech funding?
Investors need to know whether the company owns its inventions, code, data, lab outputs, patents and founder-created technology before investing.
Founder / Business Takeaway
Deeptech funding depends on evidence, IP control and compliance readiness as much as storytelling.
Need expert support?
BSA helps funded and fundraising startups prepare cap tables, FEMA documents, ESOP records, IP assignment trails, contracts and investor data rooms.
Need expert support?
BSA supports founders across India with ROC, FEMA, due diligence, fundraising readiness, and company secretarial execution.
